Browse by SDGs / 依聯合國永續發展目標主題瀏覽
SDG-01SDG-02SDG-03SDG-04SDG-05SDG-06SDG-07SDG-08SDG-09SDG-10SDG-11SDG-12SDG-13SDG-14SDG-15SDG-16
Recent Additions
  • Some of the metrics are blocked by your 
    Publication
    Association of Polycystic Ovary Syndrome With Sensorineural Hearing Loss: A Systematic Review and Meta-analysis.
    (2024-12-25)
    Chen, Tai-Yu
    ;
    ;
    Lien, Kuang-Hsu
    Objective: Despite certain studies indicating hearing impairments in individuals with polycystic ovary syndrome (PCOS), the correlation between PCOS and sensorineural hearing loss (SNHL) remains inconclusive. This study aimed to investigate the association between PCOS and SNHL. Data Sources: A systematic literature search was conducted using PubMed, MEDLINE, EMBASE, and the Cochrane Library from inception to June 24, 2024. Review Methods: This meta-analysis included cross-sectional, case-control, or cohort studies examining the association between PCOS and SNHL without language or regional restrictions. Case reports, case series, animal studies, and in vitro studies were excluded. We adhered to Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines and utilized the Newcastle-Ottawa Scale to assess the risk of bias in the included studies. Results: After performing the systematic review, we conducted a meta-analysis that included 489 patients from 5 studies: 349 patients with PCOS and 140 age- and sex-matched controls without PCOS. The meta-analysis compared the mean differences in frequency-specific pure-tone thresholds between patients with PCOS and matched controls, providing 95% confidence intervals for these differences. Given the expected clinical heterogeneity, we employed the DerSimonian and Laird random-effects model. Our results revealed significant hearing loss at specific frequencies (1000, 4000, 8000, 10,000, 12,000, 14,000, 16,000, 18,000, and 20,000 Hz) in the PCOS group compared to the control group (P <.05). Furthermore, the degree of hearing loss is greater at higher frequencies. Conclusion: This meta-analysis demonstrated an association between PCOS and SNHL, particularly at higher frequencies.
  • Some of the metrics are blocked by your 
    Publication
    Statins Reduce the Risk of Cirrhosis and Its Decompensation in Chronic Hepatitis B Patients: A Nationwide Cohort Study.
    (2016-07) ;
    Lee, Chia-Long
    ;
    Yang, Sien-Sing
    ;
    Fu, Szu-Chieh
    ;
    Chen, Yun-Yi
    ;
    Wang, Ting-Chuan
    ;
    Hu, Jui-Ting
    ;
    Ding-Shinn Chen
    The protective effect of statins in cirrhosis and its decompensation in chronic hepatitis B (CHB) patients remains unknown. We conducted a population-based cohort study using data from the Taiwanese National Health Insurance Research Database from 1997 to 2009. A total of 298,761 CHB patients were identified. CHB patients using statins (n=6,543; defined as ≥28 cumulative defined daily doses (cDDD)) and a 1:1 ratio propensity score and inception point (the date of first use of statins)-matched non-statins (<28 cDDD) were followed up from the inception point until the development of cirrhosis or its decompensation or until withdrawal from insurance or December 2009. After adjustment for competing mortality, CHB patients using statins had a significantly lower cumulative incidence of cirrhosis (relative risk)=0.433; 95% confidence interval (CI)=0.344-0.515; modified log-rank test, P<0.001) and decompensated cirrhosis (relative risk=0.468; 95% CI=0.344-0.637; P<0.001) compared with patients not using statins. After adjustment for age, gender, comorbidity index, hypertension, diabetes, hyperlipidemia, hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, aspirin use, diabetes medication, CHB treatment, non-statin lipid-lowering drugs, and triglyceride lipid-lowering drugs using the Cox proportional hazard model, statins were still an independent protector against cirrhosis (adjusted hazard ratio (AHR)=0.512; 95% CI=0.413-0.634; P<0.001) and its decompensation (AHR=0.534; 95% CI=0.433-0.659; P<0.001). The AHRs for cirrhosis were 0.467 and 0.200, and the AHRs for decompensated cirrhosis were 0.611 and 0.231 with 91-365 and >365 cDDD of statins, respectively. CHB patients who receive statin therapy have a dose-dependent reduction in the risk of cirrhosis and its decompensation.
    Scopus© Citations 93
  • Some of the metrics are blocked by your 
    Publication
    The role of PM2.5 exposure in lung cancer: mechanisms, genetic factors, and clinical implications.
    (2024)
    Chen, Chi-Yuan
    ;
    Huang, Kuo-Yen
    ;
    Chen, Chin-Chuan
    ;
    Chang, Ya-Hsuan
    ;
    Li, Hsin-Jung
    ;
    Wang, Tong-Hong
    ;
    Lung cancer is one of the most critical global health threats, as the second most common cancer and leading cause of cancer deaths globally. While smoking is the primary risk factor, an increasing number of cases occur in nonsmokers, with lung cancer in nonsmokers (LCNS) now recognized as the fifth leading cause of cancer mortality worldwide. Recent evidence identifies air pollution, particularly fine particulate matter (PM2.5), as a significant risk factor in LCNS. PM2.5 can increase oxidative stress and inflammation, induce genetic alterations and activation of oncogenes (including the epidermal growth factor receptor, EGFR), and contribute to lung cancer progression. This review summarizes the current understanding of how exposure to PM2.5 induces lung carcinogenesis and accelerates lung cancer development. It underscores the importance of prevention and early detection while calling for targeted therapies to combat the detrimental effects of air pollution. An integrated approach that combines research, public health policy, and clinical practice is essential to reduce the lung cancer burden and improve outcomes for those affected by PM2.5 exposurrre.
  • Some of the metrics are blocked by your 
    Publication
    Lung cancer research and treatment: global perspectives and strategic calls to action.
    (2024-12)
    Meyer, M-L
    ;
    Peters, S
    ;
    Mok, T S
    ;
    Lam, S
    ;
    ;
    Aggarwal, C
    ;
    Brahmer, J
    ;
    Dziadziuszko, R
    ;
    Felip, E
    ;
    Ferris, A
    ;
    Forde, P M
    ;
    Gray, J
    ;
    Gros, L
    ;
    Halmos, B
    ;
    Herbst, R
    ;
    Jänne, P A
    ;
    Johnson, B E
    ;
    Kelly, K
    ;
    Leighl, N B
    ;
    Liu, S
    ;
    Lowy, I
    ;
    Marron, T U
    ;
    Paz-Ares, L
    ;
    Rizvi, N
    ;
    Rudin, C M
    ;
    Shum, E
    ;
    Stahel, R
    ;
    Trunova, N
    ;
    Bunn, P A
    ;
    Hirsch, F R
    Background: Lung cancer remains a critical public health issue, presenting multifaceted challenges in prevention, diagnosis, and treatment. This article aims to review the current landscape of lung cancer research and management, delineate the persistent challenges, and outline pragmatic solutions. Materials and methods: Global experts from academia, regulatory agencies such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA), the National Cancer Institute (NCI), professional societies, the pharmaceutical and biotech industries, and patient advocacy groups were gathered by the New York Lung Cancer Foundation to review the state of the art in lung cancer and to formulate calls to action. Results: Improving lung cancer management and research involves promoting tobacco cessation, identifying individuals at risk who could benefit from early detection programs, and addressing treatment-related toxicities. Efforts should focus on conducting well-designed trials to determine the optimal treatment sequence. Research into innovative biomarkers and therapies is crucial for more personalized treatment. Ensuring access to appropriate care for all patients, whether enrolled in clinical trials or not, must remain a priority. Conclusions: Lung cancer is a major health burden worldwide, and its treatment has become increasingly complex over the past two decades. Improvement in lung cancer management and research requires unified messaging and global collaboration, expanded education, and greater access to screening, biomarker testing, treatment, as well as increased representativeness, participation, and diversity in clinical trials.
  • Some of the metrics are blocked by your 
    Publication
    Genetic investigations of autosomal recessive inherited ichthyosis impressed by fetal ultrasound: Exome sequencing and haplotype linkage analysis.
    (2025-01)
    Chang, Ting-Yu
    ;
    Lim, Zhu Wei
    ;
    Chu, Yi-Tzu
    ;
    Wu, Wan-Ju
    ;
    Lee, Mei-Hui
    ;
    Chang, Shun-Ping
    ;
    Lee, Dong-Jay
    ;
    Lin, Wen-Hsiang
    ;
    Ho, Ming
    ;
    ;
    Ma, Gwo-Chin
    ;
    MING CHEN 
    Objective: Ichthyosis are complex skin diseases, characterized by hyperkeratosis with various degrees of thickening, desquamation, and erythema. The prenatal diagnosis of ichthyosis is challenged due to the clinical and genetic heterogeneity and the late-onset of fetal features on ultrasound scan. Here, we reported two fetuses with Harlequin ichthyosis (HI), a severe subtype of autosomal recessive congenital ichthyosis (ARCI), who were diagnosed prenatally by images and genetic investigations. Preimplantation genetic testing (PGT) was also performed in one case and the family to prevent the transmission of this condition. Materials and methods: Fetal images were analyzed by detailed fetal ultrasound. Genetic defects in affected fetuses were detected using whole exome sequencing (WES) and confirmed by Sanger sequencing. PGT for monogenic disease (PGT-M) was performed using short tandem repeat (STR) markers and amplification refractory mutation system quantitative polymerase chain reaction (ARMS-qPCR). Results: WES identified pathogenic mutations in ABCA12 gene in both fetuses. Genome Analysis ToolKit (GATK 4 version 4.2.1.0) was merged using a setting of the trio model for exome variation analysis. Confirmatory Sanger sequencing of ABCA12 gene was also applied to both parents. Disease-cause haplotyping by STR markers and ARMS-qPCR for PGT-M strategy were conducted in family 1. Linkage analysis in conjunction with STR was used in the first case, whereas unequal coverage of WES was deciphered with the inspiration of the second case a few years later. Both cases were diagnosed by high coverage WES and led to successful subsequent pregnancies by preimplantation genetic diagnosis and genetic amniocentesis. Conclusion: Preimplantation genetic testing using STR linkage analysis can rescue cases with autosomal recessive inheritance when only one mutation is found in the putative gene, while reanalysis of high-coverage WES by optimized updated bioinformatics should always be considered in addition to whole genome sequencing.
Most viewed